Hualv Biotech (300970.SZ) released its performance for the first three quarters, with a net loss of 35.0899 million yuan.

Zhitong Finance · Oct 29 00:11

Hua Lu Biological (300970.SZ) released its third quarter report for 2024, with the company's revenue for the first three quarters reaching 7...

According to the Zhitong Finance APP, Hua Lu Biological (300970.SZ) released its third quarter report for 2024. The company's revenue for the first three quarters was 0.735 billion yuan, a decrease of 2.07% year-on-year. The net loss attributable to the shareholders of the listed company was 35.0899 million yuan. The net loss attributable to the shareholders of the listed company after deducting non-recurring gains and losses was 36.1895 million yuan. The basic loss per share was 0.3017 yuan.

The translation is provided by third-party software.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.

华绿生物(300970.SZ)发布前三季度业绩，净亏损3508.99万元

Hualv Biotech (300970.SZ) released its performance for the first three quarters, with a net loss of 35.0899 million yuan.

Risk Disclaimer

Statement